ALFA Filings
Every announcement, straight from the exchange
Reference market data from a third-party provider, updated daily. Not a valuation or a recommendation.
Announcement type
Time
10 announcements
Surbhi Singh (Prasid Uno Family Trust), a non-promoter, sold 21.30 lakh Entero Healthcare shares via bulk/block deals. Stake fell from 7.94% to 3.05%; no transaction value disclosed.
Entero Healthcare Solutions reported a GST penalty of Rs. 0.13 Crore imposed on its subsidiary, ACE Cardiopathy Solutions, for non-generation of an E-Invoice.
Entero Healthcare Solutions Ltd filed its quarterly shareholding pattern for the period ended March 31, 2026, as per regulatory requirements.
Entero delivered a strong Q1 FY27 with 38.2% revenue growth and hit its full-year EBITDA margin target of 5% in the first quarter itself, signaling rapid structural margin expansion.
Q1FY27 revenue grew 38.2% YoY to ₹1,940.5 Cr with significant margin expansion. Strategy focuses on MedTech scaling and consolidating India's fragmented pharmaceutical distribution market.
Entero Healthcare Solutions Ltd reported revenue from operations of ₹1,940 Cr (+38.2% YoY) and net profit of ₹52.1 Cr (+72.5% YoY) for Q1 FY27.
Entero delivered solid FY26 results, meeting all guidance parameters. Management transitions focus toward organic growth and margin expansion through technology-led scaling and higher-margin MedTech distribution.
Entero Healthcare delivered on its FY26 guidance with 31.5% like-for-like revenue growth and 4% EBITDA margins. Management transitioned to organic growth and profitability, focusing on higher-margin MedTech segments.
Entero delivered strong FY26 performance meeting all guidance parameters. Revenue grew 29.3% to ₹6,591 Cr with EBITDA margins expanding to 4.0%, driven by organic growth and 7 strategic acquisitions.
Entero Healthcare Solutions Ltd reported revenue from operations of ₹1,910 Cr (+42.6% YoY) and net profit of ₹45.1 Cr (+43.6% YoY) for Q4 FY26.